CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggresive non-Hodgkin's lymphoma: A pilot study

European Journal of Haematology

Volumn 65, Issue 3, 2000, Pages 188-194

  Niitsu, Nozomi ^a,f   Okamoto, Masataka ^b   Kuraishi, Yasuaki ^c   Nakamura, Shinobu ^d   Kodama, Fumio ^e   Hirano, Masami ^b  

^a TOHO UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JIKEI UNIVERSITY HOSPITAL   (Japan)

^d KANAZAWA UNIVERSITY   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

^f TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aggressive non Hodgkin's lymphoma; CyclOBEAP regimen; Granulocyte colony stimulating factor; International Prognostic Index

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; VINCRISTINE;

ADULT; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GRANULOCYTOPENIA; HUMAN; LIVER DYSFUNCTION; MALE; NAUSEA; NONHODGKIN LYMPHOMA; PARESTHESIA; PRIORITY JOURNAL; PROGNOSIS; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISOLONE; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0033857761     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.00250.x     Document Type: Article

References (27)

1. MACOP-B chemotherapy for the treatment ofdiffuse large cell lymphoma
2. Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy. A pilot study
3. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-cytaBOM: A groupwide Southwest Oncology Group study
4. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
5. CHOP is the current standard for the treatment of high risk patients with diffuse large cell lymphoma
6. International non-Hodgkin's lymphoma prognostic factors project: A predictive model for aggressive non-Hodgkin's lymphoma
7. Dose escalation of biweekly cyclophosphamide, doxorubicin vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma
8. Dose intensity in cancer chemotherapy
9. Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma
10. Nonparametric estimation from incomplete observation
11. The importance of dose intensity in chemotherapy of metastatic breast cancer
12. National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project
13. Lymphoma classification: The gap between biology and clinical management is closing
14. Report of the Committee on Hodgkin's Disease Staging Classification
15. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma
16. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group
17. CHOP versus MACOP-B in aggressive lymphoma - A Nordic Lymphoma Group randomised trial
18. The chemotherapy of lymphoma - Looking back, moving forward: The Richard and Hinda Rosenthal Foundation Award Lecture
19. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis
20. The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity
21. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity
22. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study
23. Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin, and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate and high grade non-Hodgkin's lymphoma
24. A phase I trial of high dose ProMACE-Cyta BOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma
25. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
26. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: Report of the jury